In mouse models, short-term dasatinib administration effectively prevents cytokine release syndrome (CRS), with CAR-T cell function rapidly restored upon drug withdrawal (22); building on this rationale, a single-center, two-arm phase I trial (NCT04603872) is investigating dasatinib in combination with CD19/BCMA-targeted CAR-T cells in patients with relapsed or refractory B-cell hematologic malignancies (planned enrollment of 120 patients, including B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, and Multiple Myeloma). Here, TNFRSF17 is linked to plasma cell myeloma.